Gastrointestinal Stromal Tumors Treated with Imatinib: Monitoring Response with Contrast-Enhanced Sonography

Lassau, Nathalie; Lamuraglia, Michele; Chami, L.; Leclère, J.; Bonvalot, Sylvie; Terrier, Philippe; Roche, Alain; Cesne, Axel Le

doi:10.2214/ajr.05.1192

Cited by 185 publications

(106 citation statements)

References 30 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, if mutation status is not determined before treatment, we may also check response very early by computed tomography, positron emission tomography, or contrast-enhanced ultrasound. 10 If a radiographic response is detected within a month, then the mutation status is likely favorable, and the treatment may be continued without necessarily pursuing mutation testing. If not, then mutation status should be investigated before continuing the treatment.…”

Section: Primary Diseasementioning

confidence: 99%

The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones

Gronchi¹,

Raut

2011

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

Section: Primary Diseasementioning

confidence: 99%

The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones

Gronchi¹,

Raut

2011

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Our data bring up the first evidence of (a) a host-derived factor in dictating GIST outcome during IM therapy (3,44,45), of (b) a prognostic effect of NK cell functions in solid tumors, and of (c) an immunologic ''off-target'' effect on NK cells of a tyrosine kinase inhibitor. A larger patient series will be needed to validate the prognostic value of an augmented NK cell IFN-g production at 2 months of IM therapy and to establish the added value of this immunologic parameter over that of the c-kit mutation status or ultrasonography (46). …”

Section: Discussionmentioning

confidence: 99%

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

et al. 2009

Self Cite

View full text Add to dashboard Cite

Clinical outcomes of gastrointestinal stromal tumor (GIST)-bearing patients treated with imatinib mesylate (IM) are variable. Other than the site of mutation within the c-kit gene, prognostic features of GIST remain undefined. IM can exhibit off-target effects such as triggering natural killer (NK) cell activity. We addressed whether NK cell functions could predict long term survival with IM. NK cell functions were followed up in 77 GIST patients enrolled onto two phase III trials. ''Immunologic responders'' were defined as patients whose NK cell IFN-; values after 2 months of IM were higher than or equal to the baseline value at entry into the trial. The prognostic effect of IFN-; on progression-free survival was assessed by a Wald test in a Cox regression analysis using the landmark method and stratified by trial and on the c-kit mutational status. Fifty-six patients were evaluable for the NK cell IFN-; responses at baseline and 2 months. Their median follow-up for progression-free survival was 3.7 years. Thirtyfour of 56 patients were immunologic responders to IM. In the Cox regression analysis, immunologic responders possessed a hazard ratio of progression or death equal to 0.29 (95% confidence interval, 0.12-0.70; P = 0.006) compared with nonresponders. Kaplan-Meier 2-year survival estimates were 85% for immunologic responders and 50% for nonresponders. Moreover, the immunologic response added prognostic value to the c-kit mutation. The NK cell IFN-; production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with

show abstract

“…These studies have indicated that DCE-US parameters may be correlated with tumor responses, for example in RCC with sorafenib (7,8) or in gastrointestinal stromal tumors (GIST) treated by imatinib (9).…”

Section: )mentioning

confidence: 99%

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

Lassau

Koscielny

Albigès

et al. 2010

Clinical Cancer Research

Self Cite

170

116

View full text Add to dashboard Cite

Purpose: To determine the utility of dynamic contrast-enhanced ultrasonography (DCE-US) as a prognostic tool for metastatic renal cell carcinoma patients receiving sunitinib and to identify DCE-US parameters that correlate with early treatment response.Experimental Design: Thirty-eight patients received 50 mg/d sunitinib on schedule 4/2 (4 weeks on followed by 2 weeks off treatment). After two cycles, response evaluation criteria in solid tumors were used to classify patients as responders or nonresponders. DCE-US evaluations were done before treatment and at day 15; variations between days 0 and 15 were calculated for seven DCE-US functional parameters and were compared for responders and nonresponders. The correlation between DCE-US parameters and disease-free survival (DFS) and overall survival (OS) was assessed.Results: The ratio between DCE-US examinations at baseline and day 15 significantly correlated with response in five of the seven DCE-US parameters. Two DCE-US parameters (time to peak intensity and slope of the wash-in) were significantly associated with DFS; time to peak intensity was also significantly associated with OS.Conclusions: DCE-US is a useful tool for predicting the early efficacy of sunitinib in metastatic renal cell carcinoma patients. Robust correlations were observed between functional parameters and classic assessments, including DFS and OS. Clin Cancer Res; 16(4); 1216-25. ©2010 AACR.

show abstract

Gastrointestinal Stromal Tumors Treated with Imatinib: Monitoring Response with Contrast-Enhanced Sonography

Abstract: Contrast-enhanced Doppler sonography is a noninvasive imaging technique that allows the early prediction of tumor response in c-kit-positive GIST treated with Glivec.

Cited by 185 publications

References 30 publications

The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones

The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

Contact Info

Product

Resources

About